Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 346,600 shares of the biopharmaceutical company’s stock after acquiring an additional 5,266 shares during the period. Commonwealth Equity Services LLC’s holdings in Gilead Sciences were worth $26,713,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Gilead Sciences by 98,797.6% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock worth $30,366,034,000 after purchasing an additional 393,607,491 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter worth $1,115,186,000. Moneta Group Investment Advisors LLC raised its position in shares of Gilead Sciences by 96,759.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after purchasing an additional 10,100,755 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on GILD shares. Truist Financial restated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a report on Wednesday, September 6th. Piper Sandler reduced their price target on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, July 24th. HSBC initiated coverage on Gilead Sciences in a research report on Wednesday, September 6th. They issued a “reduce” rating and a $71.00 target price for the company. Barclays dropped their price target on Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, July 24th. Finally, Leerink Partnrs restated a “market perform” rating on shares of Gilead Sciences in a research report on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $88.22.

Gilead Sciences Stock Up 1.2 %

Shares of GILD stock opened at $75.45 on Monday. The stock’s 50 day simple moving average is $76.82 and its 200 day simple moving average is $77.26. Gilead Sciences, Inc. has a twelve month low of $72.87 and a twelve month high of $89.74. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34. The company has a market capitalization of $94.01 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.00 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. The company had revenue of $7.05 billion for the quarter, compared to analyst estimates of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post 6.76 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.75 dividend. The ex-dividend date is Thursday, December 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.98%. Gilead Sciences’s payout ratio is presently 64.38%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 1,501 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the transaction, the insider now owns 70,130 shares in the company, valued at approximately $5,399,308.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief financial officer now owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.